© The Financial Times Ltd 2014 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Nov 22, 2014, the consensus forecast amongst 6 polled investment analysts covering CTI BioPharma Corp advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Nov 04, 2013. The previous consensus forecast advised investors to purchase equity in CTI BioPharma Corp.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 5 analysts offering 12 month price targets for
Dividend information is not available for
On Oct 29, 2014,
|Average growth rate||+5.00%|
|Average growth rate||+45.22%|
CTI BioPharma Corp. had 3rd quarter 2014 revenues of 39.53m. This bettered the 25.00m consensus of the 4 analysts covering the company. This was 2,843.71% above the prior year's 3rd quarter results. View Full Interim Financials
|Average growth rate||+763.47%|
CTI BioPharma Corp. had revenues for the full year 2013 of 2.31m. View Full Annual Financials
|Average growth rate||+66.25%|